BeiGene (ONC) announced the U.S. FDA has approved Ttevimbra in combination with platinum-containing chemotherapy, for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma whose tumors express PD-L1.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONC:
- BeiGene upgraded to Buy from Neutral at BofA
- BeiGene’s Strong Market Position and Growth Potential Driven by Zanubrutinib Sales and Promising Financial Outlook
- BeiGene’s Strong Financial Performance and Promising Outlook Earns Buy Rating from Analyst
- BeiGene granted orphan designation for sonrotoclax
- BeiGene price target raised to $313 from $259 at Macquarie